Mystical but not challenging experiences predict symptom improvement after psilocybin for treatment-resistant OCD

Read full text
Authors: Sarah Shnayder, Gabrielle Agin-Liebes, Troy Hubert, Terence H. W. Ching, Jamila Hokanson, Christopher Pittenger, Benjamin Kelmendi, Thomas G. Adams
Cited by: 0
References: 43

Abstract

Background: Psilocybin treatment has shown promise across a range of psychiatric conditions. Mystical-type experiences during dosing sessions have been shown to predict the clinical effects of psilocybin treatment in depression, anxiety, and addiction. However, no studies have examined whether acute subjective experiences predict treatment response in obsessive-compulsive disorder (OCD). Methods: Exploratory analyses were conducted using data from participants with treatment-resistant OCD who received psilocybin as part of a randomized, double-blind, placebo-controlled trial and subsequent open-label phase. Twenty-seven participants who received psilocybin (0.25 mg/kg) completed the Mystical Experience Questionnaire (MEQ-30) and Challenging Experience Questionnaire (CEQ) the day following their session. OCD severity was assessed using the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) at baseline and at 1- and 12-week follow-up. Results: Greater mystical-type experiences during psilocybin were associated with lower OCD symptom severity at 1- and 12-week follow-up, even after controlling for baseline OCD symptom severity and treatment condition. The Mystical subscale demonstrated the strongest and most consistent associations at both time points, while the Space-Time subscale was only associated with lower Y-BOCS at 12 weeks. The Positive Mood and Ineffability subscales were not significantly associated with post-treatment OCD symptom severity after correction for multiple comparisons. Challenging experiences were not significantly associated with post-treatment OCD severity. Conclusions: Mystical experiences - particularly experiences of unity, sacredness, and transcendence - during psilocybin sessions are associated with greater OCD symptom reduction. These findings support attention to experiential quality in psilocybin-assisted therapy and have implications for optimizing treatment through dosing, set, setting, and integration practices.

Fields of Study & Subjects

Psychedelics and Drug Studies Obsessive-Compulsive Spectrum Disorders Religion Spirituality and Psychology

Publication details

Journal / source
Frontiers in Psychiatry
Volume
17
Pages
1799543–1799543
Publication date
8 September 2026
Language
EN